GSK And Theravance Withdraw Japan NDA for Relvar COPD Indication
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline PLC and Theravance announced July 12 the withdrawal of a new drug application in Japan for a chronic obstructive pulmonary disease indication of Relvar/Ellipta (fluticasone furoate/vilanterol), but is preparing a resubmission.